PF-Atlas › Mechanisms › BCL-2/BCL-XL inhibitor — more potent senolytic than D+Q
BCL-2/BCL-XL inhibitor — more potent senolytic than D+Q in IPF
Mechanism of action · idiopathic pulmonary fibrosis
Overview
BCL-2/BCL-XL inhibitor — more potent senolytic than D+Q is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 1 drug and 0 clinical trials acting through this mechanism.
Drugs targeting BCL-2/BCL-XL inhibitor — more potent senolytic than D+Q
Therapies
Medical disclaimer. This is a research summary, not medical advice.